We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 1

Figure 1. From: Cancer Immunology - Analysis of Host and Tumor Factors for Personalized Medicine.

Various immune-cell reaction patterns can be observed upon pathologic examination of a cancer biopsy. The level of immune-cell infiltration varies widely between tumors (from absent to intense); tumors with considerable immune reactions are depicted. a | Lymphocytic infiltrates in tumor stroma (arrowheads) between glandular structures formed by neoplastic cells, as well as on top of neoplastic cells (arrows) as a form of tumor-infiltrating lymphocytes (magnification, ×100). b | Tumor-infiltrating lymphocytes from part a (arrows) are shown in a high-power view (magnification, ×400). c | Immune reactions surround the tumor as a form of peritumoral lymphocytic reaction (empty arrowhead), and are observed in smooth muscle and adipose tissue (empty arrows) with some distance from tumor (magnification, ×40).

Shuji Ogino, et al. Nat Rev Clin Oncol. ;8(12):711-719.
2.
Figure 2

Figure 2. From: Cancer Immunology - Analysis of Host and Tumor Factors for Personalized Medicine.

Putative inter-relationship between tumor molecular changes, host immune response, regional lymph nodes, disease stage and prognosis in colorectal cancer. Tumor molecular changes are associated with both the host immune response and with patient prognosis.45,49,52 The host immune response is associated with early-stage disease and an increased number of lymph nodes detected in resection specimens.138 Immune reaction may promote proliferation of lymphocytes and enlargement of regional lymph nodes, potentially facilitating lymph-node dissection in gross pathology examination and increasing in the number of recovered lymph nodes. The lymph-node count is associated with good prognosis, independent of the host immune response, tumor stage and tumor molecular variables.138 Thus, a comprehensive assessment of host immune response, disease staging, node count, and tumor molecular variables is necessary to evaluate the clinical utility of host immune response evaluation.

Shuji Ogino, et al. Nat Rev Clin Oncol. ;8(12):711-719.

Supplemental Content

Recent activity

Your browsing activity is temporarily unavailable.

Write to the Help Desk